Chardan Capital Raises Zura Bio (NASDAQ:ZURA) Price Target to $11.00

Zura Bio (NASDAQ:ZURA) had its price target hoisted by equities researchers at Chardan Capital from $10.00 to $11.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s price objective indicates a potential upside of 104.46% from the stock’s previous close.

Several other brokerages have also recently commented on ZURA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Oppenheimer reduced their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. Finally, Wedbush started coverage on Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Price Performance

Shares of ZURA stock opened at $5.38 on Monday. The company has a market cap of $349.81 million, a price-to-earnings ratio of -5.08 and a beta of 0.18. Zura Bio has a 1 year low of $0.97 and a 1 year high of $7.44. The firm has a fifty day moving average price of $6.18 and a 200-day moving average price of $4.61.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.31). Equities research analysts expect that Zura Bio will post -0.65 EPS for the current year.

Insider Activity at Zura Bio

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was bought at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the transaction, the insider owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP purchased a new position in shares of Zura Bio in the 4th quarter worth approximately $30,000. Scientech Research LLC purchased a new stake in Zura Bio during the 3rd quarter valued at $45,000. AQR Capital Management LLC purchased a new stake in Zura Bio during the 1st quarter valued at $72,000. Forefront Wealth Partners LLC bought a new stake in Zura Bio in the third quarter worth $93,000. Finally, Bank of America Corp DE lifted its position in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after buying an additional 9,966 shares during the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.